CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 185 enrolled
Drug / intervention
ciclesonide hydrofluoroalkane (HFA) nasal aerosol +1 moredrug
Likely dose
ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01287364
NCT01287364Phase 3Completed
CompareCT.gov

Psychometric Evaluation of a Novel Questionnaire Designed to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids Administered Via HFA Aerosol or Aqueous Suspension Used for the Treatment of Allergic Rhinitis

Sumitomo Pharma America, Inc.·interventional·Posted Feb 1, 2011·Updated Nov 2, 2012

In Brief

A Phase 3 clinical trial evaluating ciclesonide hydrofluoroalkane (HFA) nasal aerosol and mometasone nasal inhalation for Perennial Allergic Rhinitis. Completed, enrolled 185 participants across 6 sites.

Detailed Summary

This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of treatment satisfaction with and preference of an Internasal Corticosteroid (INCS)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.4 years ago

Interventions

ciclesonide hydrofluoroalkane (HFA) nasal aerosoldrug

ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.

mometasone nasal inhalationdrug

mometasone nasal inhalation 200 μg once daily for one week